XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Operating Costs and Expenses:        
General and administrative $ 2,302 $ 212 $ 5,702 $ 5,099
Research and development 2,734 4,006 9,145 10,115
In-process research and development impairment 1,325   1,325  
Goodwill impairment 1,526   5,594  
Total Operating Costs and Expenses 7,887 4,218 21,766 15,214
Loss from Operations (7,887) (4,218) (21,766) (15,214)
Other Income/Expense:        
Foreign currency exchange gain 3 6 1 7
Interest income 158 382 559 1,127
Total Other Income 161 388 560 1,134
Net Loss (7,726) (3,830) (21,206) (14,080)
Income tax benefit   527   1,216
Net Loss Attributable to Common Stockholders $ (7,726) $ (3,303) $ (21,206) $ (12,864)
Net Loss Per Share - Basic (in dollars per share) $ (6.81) $ (4.85) $ (24.47) $ (20.38)
Net Loss Per Share - Dilutive (in dollars per share) $ (6.81) $ (4.85) $ (24.47) $ (20.38)
Weighted average number of shares outstanding during the period - Basic (in shares) 1,134,391 681,708 866,529 631,387
Weighted average number of shares outstanding during the period - dilutive (in shares) 1,134,391 681,708 866,529 631,387
Net Loss $ (7,726) $ (3,303) $ (21,206) $ (12,864)
Gain (Loss) on foreign currency translation 821 (702) 80 (379)
Total comprehensive loss $ (6,905) $ (4,005) $ (21,126) $ (13,243)